Immune Therapeutics, Inc. (IMUN) Offers Update on Methionine-Enkelphine Drug Development Program in China
Before the opening bell, Immune Therapeutics, Inc. (OTCQB: IMUN) offered shareholders an update of the status of its ongoing drug development program in China. Recently, Chinese Peptide Company (CPC), one of only a handful of companies in the world that can claim both ISO Certification and cGMP licensing, completed the formulation and required Chemistry, Manufacturing and Controls (CMC) for Methionine-Enkelphine (MENK). IMUN’s long-term partner, Hubei Qianjiang Pharmaceutical Co. Ltd. (Qianjiang), is expected to provide formulation and CMC data to Cytocom, Inc., a subsidiary of IMUN, within 30 days. With this data in hand, Cytocom will take the necessary steps to…